SCHEMBL11920019

SCHEMBL11920019

c1ccc(-n2c(SCCCc3nc(-c4ccncc4)no3)nnc2-c2ccncc2)cc1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 2/20 0.69
▸ HTT P42858 1/20 0.69
▸ TNKS2 Q9H2K2 7/20 0.68
▸ TP53 P04637 5/20 0.66
▸ SMN1; SMN2 Q16637 4/20 0.66
▸ TNKS O95271 4/20 0.64
▸ NPSR1 Q6W5P4 2/20 0.63
▸ MAPT P10636 5/20 0.59
▸ THRB P10828 2/20 0.59
▸ MEN1 O00255 1/20 0.58
▸ ALDH1A1 P00352 1/20 0.58
▸ KMT2A Q03164 1/20 0.58
▸ HDAC2 Q92769 2/20 0.58
▸ HDAC3 O15379 1/20 0.58
▸ PTK2 Q05397 1/20 0.58
▸ HDAC1 Q13547 1/20 0.58
▸ HDAC8 Q9BY41 1/20 0.58
▸ HDAC6 Q9UBN7 1/20 0.58
▸ CYP3A4 P08684 1/20 0.56
▸ CYP2D6 P10635 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11920020 0.84 KDM4E (0.57) LMNAHTTTNKS2TP53SMN1; SMN2
SCHEMBL13046997 0.80 NPSR1 (0.74) LMNAHTTTNKS2TP53SMN1; SMN2
SCHEMBL11919900 0.78 TNKS2 (0.83) LMNATNKS2TP53SMN1; SMN2TNKS
SCHEMBL16010756 0.78 TNKS2 (1.00) LMNAHTTTNKS2TP53SMN1; SMN2
SCHEMBL13046998 0.73 NPSR1 (0.90) LMNAHTTTNKS2TP53SMN1; SMN2
SCHEMBL11919901 0.73 TP53 (1.00) LMNAHTTTNKS2TP53SMN1; SMN2
SCHEMBL11920016 0.73 TP53 (0.84) LMNAHTTTNKS2TP53SMN1; SMN2
SCHEMBL11919909 0.73 TP53 (0.84) LMNAHTTTNKS2TP53SMN1; SMN2
SCHEMBL13048271 0.73 TP53 (0.84) LMNAHTTTNKS2TP53SMN1; SMN2
SCHEMBL16486612 0.72 TNKS2 (0.67) LMNAHTTTNKS2NPSR1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8883827-B2 Azole derivatives as WTN pathway inhibitors OSLO UNIVERSITY HOSPITAL HF (NO) 2014-11-11 — — US disclosed
US-8883827-B2 Azole derivatives as WTN pathway inhibitors OSLO UNIVERSITY HOSPITAL HF (NO) 2014-11-11 — — US disclosed
US-20120208828-A1 Azole Derivatives as WTN Pathway Inhibitors OSLO UNIVERSITY HOSPITAL HF (NO) 2012-08-16 — — US disclosed
US-20120208828-A1 Azole Derivatives as WTN Pathway Inhibitors OSLO UNIVERSITY HOSPITAL HF (NO) 2012-08-16 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120208828-A1 Azole Derivatives as WTN Pathway Inhibitors WNT1, AXIN2, WNT3 LMNA 1015/4885HTT 4649/4885TNKS2 1460/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback